Prenosis Announces $20M BARDA Contract and $20M Series A Financing Round, Advancing Mission to Deliver Integrated Diagnostics and Therapeutics
Latest fundraising efforts accelerate further innovation in biology-based diagnostics and therapeutics for critical care conditions
CHICAGO, IL – January 29, 2026 – Prenosis, a biology-based technology company delivering integrated diagnostics and therapeutics, announced today two major milestones: completion of its Series A Financing Round, and a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
The combined funding from private investors and BARDA will support commercial delivery of Prenosis’ AI-based diagnostic tools, clinical trial enrollment, algorithm development and validation, and regulatory advancement. It will also support expansion of Prenosis’ precision medicine platform for additional critical care applications, including sepsis, pneumonia, acute heart failure (AHF), acute respiratory distress syndrome (ARDS), and acute kidney injury (AKI).
